Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic ...

Many doctors agree with the Food and Drug Administration’s recent decision to remove the black box warnings on at least some ...

Persistent recruitment delays, high dropout rates, and missed timelines continue to slow global clinical trials, while data show that sub-Saharan Africa offers a largely untapped opportunity with ...

Tesamorelin is a synthetic 44–amino acid analog of growth hormone–releasing hormone (GHRH) that has attracted attention outside the experimental domain for its potential as a research tool. This ...